The SPCC (Sharing Progress in Cancer Care) webinar, titled “MRD in multiple myeloma: foundations and clinical relevance,” is a high-level educational session scheduled for February 11, 2026.

As Minimal Residual Disease (MRD) transitions from a clinical trial endpoint to a critical tool for personalized oncology, this webinar aims to bridge the gap between scientific theory and daily clinical practice. Led by a panel of world-renowned experts, the session will explore how ultra-sensitive detection technologies – capable of identifying a single cancer cell among a million healthy ones – are redefining what it means for a patient to be in “remission.”